Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.99 USD | +2.73% | -10.04% | -40.32% |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- One of the major weak points of the company is its financial situation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.32% | 2.05B | C+ | ||
-4.84% | 182B | C+ | ||
+0.56% | 110B | C | ||
-3.35% | 68.11B | A | ||
+2.39% | 50.53B | B- | ||
+9.36% | 44.8B | B- | ||
+2.70% | 40.7B | B+ | ||
+3.43% | 26.53B | A- | ||
+13.67% | 25.02B | A- | ||
-0.32% | 24.96B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IART Stock
- Ratings Integra LifeSciences Holdings Corporation